| name | icsm-consider-tt-after-rp-undetectable-psa |
| description | This skill suggests testosterone therapy may be considered after radical prostatectomy when postoperative PSA is undetectable and pathology reveals negative surgical margins, negative seminal vesicles, and negative lymph nodes. It is triggered when a clinician encounters a post‑prostatectomy patient with symptomatic low testosterone and questions whether it is safe to initiate testosterone therapy or if the cancer is sufficiently cleared. |
Consider testosterone therapy after radical prostatectomy with undetectable PSA and favorable pathology
STEP 1 — Gather Information
Collect postoperative PSA value (preferably <0.01 ng/mL), pathology report assessing surgical margins, seminal vesicle involvement, and lymph node status; document symptoms of hypogonadism (low libido, fatigue, ED); obtain two morning fasting total testosterone measurements (<12 nmol/L); ensure no evidence of biochemical recurrence or active disease.
STEP 2 — Rule In / Rule Out
If PSA is undetectable and pathology shows negative margins, negative seminal vesicles, and negative lymph nodes → proceed to Step 3; otherwise → do not offer testosterone therapy and evaluate for other causes of hypogonadism or consider oncology referral.
STEP 3 — Classify or Stratify
Classify the patient as a low‑risk candidate for testosterone therapy when criteria in Step 2 are met; if any pathology feature is positive (margins, SV, nodes) or PSA detectable, defer testosterone therapy and obtain multidisciplinary input before reconsideration.
STEP 4 — Decide
Initiate testosterone therapy after shared decision‑making, targeting a mid‑normal total testosterone range; obtain baseline PSA and digital rectal examination, then follow monitoring schedule per Table4 (symptoms, adverse events, testosterone, hematocrit, PSA, DRE at baseline, 3 mo, 6 mo, and yearly).
Clinical Guardrails / Mimics / Pitfalls
Do not offer testosterone therapy if PSA is detectable, margins are positive, seminal vesicles or nodes are involved, or if there is any suspicion of biochemical recurrence; avoid monotherapy for erectile dysfunction without confirmed hypogonadism; never omit baseline PSA/DRE or ongoing prostate cancer surveillance; do not ignore patient preferences or fail to discuss potential risks of theoretical prostate cancer stimulation.
Concrete Clinical Example
A 62‑year‑old man 3 months post‑radical prostatectomy for Gleason 3+4 prostate cancer presents with fatigue and decreased libido. His PSA is <0.01 ng/mL, pathology shows negative margins, negative seminal vesicles, and negative lymph nodes. Total testosterone is 8 nmol/L on two morning samples. After discussing risks and benefits, testosterone therapy is started with plans for PSA and DRE monitoring every 3 months initially.
Source: Male hypogonadism: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024), Mohit Khera et al., Sexual Medicine Reviews, 2025, 13:548-573, https://doi.org/10.1093/sxmrev/qeaf036
